Advanced

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

Hansen, T. F.; Christensen, R. Dp; Andersen, R. F.; Sorensen, F. B.; Johnsson, Anders LU and Jakobsen, A. (2013) In British Journal of Cancer 109(5). p.1243-1251
Abstract
Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly... (More)
Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly related to a longer progression-free survival. The independent prognostic value of miRNA-126 was confirmed using a Cox regression analysis (hazard ratio = 0.49, 95% confidence interval = 0.29-0.84, P = 0.009). Although not significant, a relationship between EGFL7 expression and response rates is suggested, with EGFL7 expression at the invasive front being lower in responding patients than in the non-responders (P = 0.063). Conclusion: The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA-126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
angiogenesis, chemotherapy, colorectal neoplasms, epidermal growth, factor-like domain 7, microRNA, predictive biomarkers
in
British Journal of Cancer
volume
109
issue
5
pages
1243 - 1251
publisher
Nature Publishing Group
external identifiers
  • wos:000324168500021
  • scopus:84883742865
ISSN
1532-1827
DOI
10.1038/bjc.2013.448
language
English
LU publication?
yes
id
ef81c82e-56ed-4cae-b71a-3d20298cf43c (old id 4103141)
date added to LUP
2013-11-07 14:21:26
date last changed
2019-07-09 01:01:07
@article{ef81c82e-56ed-4cae-b71a-3d20298cf43c,
  abstract     = {Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly related to a longer progression-free survival. The independent prognostic value of miRNA-126 was confirmed using a Cox regression analysis (hazard ratio = 0.49, 95% confidence interval = 0.29-0.84, P = 0.009). Although not significant, a relationship between EGFL7 expression and response rates is suggested, with EGFL7 expression at the invasive front being lower in responding patients than in the non-responders (P = 0.063). Conclusion: The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA-126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics.},
  author       = {Hansen, T. F. and Christensen, R. Dp and Andersen, R. F. and Sorensen, F. B. and Johnsson, Anders and Jakobsen, A.},
  issn         = {1532-1827},
  keyword      = {angiogenesis,chemotherapy,colorectal neoplasms,epidermal growth,factor-like domain 7,microRNA,predictive biomarkers},
  language     = {eng},
  number       = {5},
  pages        = {1243--1251},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial},
  url          = {http://dx.doi.org/10.1038/bjc.2013.448},
  volume       = {109},
  year         = {2013},
}